October 20 - ** Shares of the world’s largest pharmaceutical company Eli Lilly (LLY.N) rose 5.45%, reaching a record high of $1,307.91
** The previous 52-week high for the stock was $1,292.65
** According to data from the London Stock Exchange Group (LSEG), Wall Street holds an overall optimistic view on this trillion-dollar market cap stock, with 29 analysts rating it as “Buy” or “Strong Buy,” 3 rating it “Hold,” and 1 rating it “Sell.” The median target price is $1,380.50
** LLY has expanded its drug research pipeline through a series of acquisitions and licensing agreements, using strong cash flow from its diabetes and weight loss drugs to drive broader M&A activity
** Other major pharmaceutical companies, including Amgen (AMGN.O), Pfizer (PFE.N), Johnson & Johnson (JNJ.N), and AbbVie (ABBV.N), also saw gains in early trading; the broader S&P 500 Health Care Index .SPXHC hit a record high
** Including today’s gains, LLY stock has climbed about 21% so far this year
(To assist non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may be inaccurate or lack the necessary context, Reuters does not guarantee the accuracy of these automated translations, which are provided solely for reader convenience. Reuters accepts no responsibility for any harm or loss resulting from the use of automated translation features.)